Fibrolamellar Carcinoma clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors.
at UCLA UCSD UCSF